Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies
Stephanie Vauleon, Katharina Schutz, Benoit Massonnet, Nanda Gruben, Marianne Manchester, Alessandra Buehler, Eginhard Schick, Lauren Boak, David J Hawellek
doi: https://doi.org/10.1101/2022.07.22.22277927
Stephanie Vauleon
1Regulated Bioanalysis, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland
Katharina Schutz
1Regulated Bioanalysis, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland
Benoit Massonnet
1Regulated Bioanalysis, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland
Nanda Gruben
2ICON Bioanalytical Laboratories, Assen, The Netherlands
Marianne Manchester
3Pharmaceutical Sciences, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland
Alessandra Buehler
1Regulated Bioanalysis, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland
Eginhard Schick
1Regulated Bioanalysis, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland
Lauren Boak
4F. Hoffmann-La Roche Ltd, Basel, Switzerland
David J Hawellek
5Biomarkers & Translational Technologies, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland
Posted July 22, 2022.
Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies
Stephanie Vauleon, Katharina Schutz, Benoit Massonnet, Nanda Gruben, Marianne Manchester, Alessandra Buehler, Eginhard Schick, Lauren Boak, David J Hawellek
medRxiv 2022.07.22.22277927; doi: https://doi.org/10.1101/2022.07.22.22277927
Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies
Stephanie Vauleon, Katharina Schutz, Benoit Massonnet, Nanda Gruben, Marianne Manchester, Alessandra Buehler, Eginhard Schick, Lauren Boak, David J Hawellek
medRxiv 2022.07.22.22277927; doi: https://doi.org/10.1101/2022.07.22.22277927
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2253)
- Dermatology (199)
- Emergency Medicine (368)
- Epidemiology (11542)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3539)
- Geriatric Medicine (336)
- Health Economics (611)
- Health Informatics (2283)
- Health Policy (909)
- Hematology (333)
- HIV/AIDS (741)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (385)
- Neurology (3322)
- Nursing (189)
- Nutrition (504)
- Oncology (1747)
- Ophthalmology (521)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (221)
- Palliative Medicine (66)
- Pathology (434)
- Pediatrics (997)
- Primary Care Research (398)
- Public and Global Health (5966)
- Radiology and Imaging (1213)
- Respiratory Medicine (806)
- Rheumatology (367)
- Sports Medicine (309)
- Surgery (383)
- Toxicology (50)
- Transplantation (169)
- Urology (142)